The BRCA1/2 deficient samples in the training set of CHORD primarily consisted of ovarian, breast, and prostate tumors, which could potentially bias CHORD’s predictions if the mutation footprint of HRD is not universal across tissue types. This evidence concerns the gene BRCA1 and prostate neoplasm.